Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Ocular Therapeutix (OCUL) over the last 10 years, with Q4 2025 value amounting to $139.8 million.

  • Ocular Therapeutix's Total Non-Current Liabilities rose 811.71% to $139.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $139.8 million, marking a year-over-year increase of 811.71%. This contributed to the annual value of $139.8 million for FY2025, which is 811.71% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Total Non-Current Liabilities is $139.8 million, which was up 811.71% from $137.7 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Total Non-Current Liabilities high stood at $139.8 million for Q4 2025, and its period low was $86.3 million during Q1 2021.
  • In the last 5 years, Ocular Therapeutix's Total Non-Current Liabilities had a median value of $109.5 million in 2023 and averaged $113.0 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Total Non-Current Liabilities soared by 3052.42% in 2021, and later tumbled by 507.7% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Total Non-Current Liabilities (Quarter) stood at $96.7 million in 2021, then grew by 11.23% to $107.6 million in 2022, then rose by 21.74% to $130.9 million in 2023, then decreased by 1.22% to $129.3 million in 2024, then grew by 8.12% to $139.8 million in 2025.
  • Its last three reported values are $139.8 million in Q4 2025, $137.7 million for Q3 2025, and $131.4 million during Q2 2025.